Aminoran daño en cirugía de mama
Por
Adriana Alatorre
|
||||||||
 | ||||||||
| ||||||||
Juan Enrique Bargallón Rocha, jefe del departamento de tumores mamarios del Instituto Nacional de Cancerología (Incan), afirmó que existe cada día una evolución en el tratamiento del cáncer.
Desde hace varios años, dijo, aprendimos que hay un grupo de pacientes que pueden conservar su mama, por las características del tumor, de las pacientes y algunas habilidades quirúrgicas.
"Eso para muchas mujeres va a permitir un impacto en la calidad de vida al preservar el órgano. Conservar feminidad, un órgano que nos parece muy importante en todos sentidos, conservarán su sensibilidad, volumen", expuso.
Al término de la primera cirugía que se realizó con una nueva tecnología alemana donada por los laboratorios Zeizz, explicó que con esta nueva tecnología se permitirá conservar el órgano de las mujeres extirpándoles el tumor.
Además, el aparato utilizado durante la operación, permite la aplicación de la radioterapia en una sola sesión.
"Lo que implica en tiempo de aplicación de radioterapias, que representa entre cinco a seis semanas que tienen que asistir las pacientes de lunes a viernes a recibir terapia, se ahorra con la aplicación el propio día de la operación", reveló el médico.
Este grupo de varias tecnologías se le denomina Irradiación Parcial Acelerada de la Mama, lo que permite aplicar la radioterapia durante la cirugía.
"La aplicación de este procedimiento es para algún número seleccionado de pacientes que en lugar de recibir seis semanas, queda tratado en unos minutos durante la cirugía", explicó.
Enfatizó que este aparato sólo se puede utilizar en un grupo seleccionado de pacientes. Explicó que, lo que ha cambiado en la medicina es que se le hace a cada quien lo que realmente necesita.
Cancer Cells Defeated by Nanotech Delivery System
Mark Hoffman
First Posted: Feb 08, 2013 04:15 PM EST
In a new application of nanotechnology to defeat cancer, a bio-degradable
nanoscale shell has been developed to carry proteins to cancer cells that signal
them to suicide. Only the cancer cells kill themselves, which stops the growth
of tumors, while healthy cells are not affected - a big difference of this
method developed by a team led by researchers from the UCLA Henry Samueli School
of Engineering and Applied Science, compared to chemotherapy that does not
discriminate between healthy and cancerous cells.
The tiny shells used are about 100 nanometers in length and are composed of a
water-soluble polymer, degrading harmlessly in non-cancerous cells. They contain
the cell-destroying material apoptin, a protein complex which was derived from
an anemia virus in birds. The protein cargo accumulates in the nucleus of cancer
cells and signals to the cell to undergo apoptosis, a programmed
self-destruction.
"This approach is potentially a new way to treat cancer," said Yi Tang, a
professor of chemical and biomolecular engineering and a member of the
California NanoSystems Institute at UCLA. "It is a difficult problem to deliver
the protein if we don't use this vehicle. This is a unique way to treat cancer
cells and leave healthy cells untouched."
Tests done on human breast cancer cell lines in laboratory mice indeed showed significant reduction in tumor growth. And the process does not present the risk for example of genetic mutation posed by gene therapies for cancer, said Tang.
The polymer shells are developed under mild physiological conditions so as not to alter the chemical structure of the proteins or cause them to clump, preserving their effectiveness on the cancer cells.
Tang's group continues to research ways of more precisely targeting tumors, prolonging the circulation time of the capsules, and delivering other highly sought-after proteins to cancer cells.
Paper:
Muxun Zhao et al., Degradable polymeric nanocapsule for efficient intracellular delivery of a high molecular weight tumor-selective protein complex, Nano Today, 2013, DOI: 10.1016/j.nantod.2012.12.003
Like
Us on Facebook
(Photo : UCLA Engineering)
A diagram showing how degradable nanocapsules are ingested into cell nuclei to induce programmed cell death in cancer cells, while degrading in normal cells.
A diagram showing how degradable nanocapsules are ingested into cell nuclei to induce programmed cell death in cancer cells, while degrading in normal cells.
Tests done on human breast cancer cell lines in laboratory mice indeed showed significant reduction in tumor growth. And the process does not present the risk for example of genetic mutation posed by gene therapies for cancer, said Tang.
The polymer shells are developed under mild physiological conditions so as not to alter the chemical structure of the proteins or cause them to clump, preserving their effectiveness on the cancer cells.
Tang's group continues to research ways of more precisely targeting tumors, prolonging the circulation time of the capsules, and delivering other highly sought-after proteins to cancer cells.
Paper:
Muxun Zhao et al., Degradable polymeric nanocapsule for efficient intracellular delivery of a high molecular weight tumor-selective protein complex, Nano Today, 2013, DOI: 10.1016/j.nantod.2012.12.003
A tiny capsule invented at a UCLA lab could go
a long way toward improving cancer
treatment.
Devising a method for more precise and less invasive treatment of cancer tumors, a team led by researchers from the UCLA Henry Samueli School of Engineering and Applied Science has developed a degradable nanoscale shell to carry proteins to cancer cells and stunt the growth of tumors without damaging healthy cells.
In a new study, published online Feb. 1 in the peer-reviewed journal Nano Today, a group led by Yi Tang, a professor of chemical and biomolecular engineering and a member of the California NanoSystems Institute at UCLA, reports developing tiny shells composed of a water-soluble polymer that safely deliver a protein complex to the nucleus of cancer cells to induce their death. The shells, which at about 100 nanometers are roughly half the size of the smallest bacterium, degrade harmlessly in non-cancerous cells.
The process does not present the risk of genetic mutation posed by gene therapies for cancer, or the risk to healthy cells caused by chemotherapy, which does not effectively discriminate between healthy and cancerous cells, Tang said.
"This approach is potentially a new way to treat cancer," said Tang. "It is a difficult problem to deliver the protein if we don't use this vehicle. This is a unique way to treat cancer cells and leave healthy cells untouched."
The cell-destroying material, apoptin, is a protein complex derived from an anemia virus in birds. This protein cargo accumulates in the nucleus of cancer cells and signals to the cell to undergo programmed self-destruction.
The polymer shells are developed under mild physiological conditions so as not to alter the chemical structure of the proteins or cause them to clump, preserving their effectiveness on the cancer cells.
Tests done on human breast cancer cell lines in laboratory mice showed significant reduction in tumor growth.
Devising a method for more precise and less invasive treatment of cancer tumors, a team led by researchers from the UCLA Henry Samueli School of Engineering and Applied Science has developed a degradable nanoscale shell to carry proteins to cancer cells and stunt the growth of tumors without damaging healthy cells.
In a new study, published online Feb. 1 in the peer-reviewed journal Nano Today, a group led by Yi Tang, a professor of chemical and biomolecular engineering and a member of the California NanoSystems Institute at UCLA, reports developing tiny shells composed of a water-soluble polymer that safely deliver a protein complex to the nucleus of cancer cells to induce their death. The shells, which at about 100 nanometers are roughly half the size of the smallest bacterium, degrade harmlessly in non-cancerous cells.
The process does not present the risk of genetic mutation posed by gene therapies for cancer, or the risk to healthy cells caused by chemotherapy, which does not effectively discriminate between healthy and cancerous cells, Tang said.
"This approach is potentially a new way to treat cancer," said Tang. "It is a difficult problem to deliver the protein if we don't use this vehicle. This is a unique way to treat cancer cells and leave healthy cells untouched."
The cell-destroying material, apoptin, is a protein complex derived from an anemia virus in birds. This protein cargo accumulates in the nucleus of cancer cells and signals to the cell to undergo programmed self-destruction.
The polymer shells are developed under mild physiological conditions so as not to alter the chemical structure of the proteins or cause them to clump, preserving their effectiveness on the cancer cells.
Tests done on human breast cancer cell lines in laboratory mice showed significant reduction in tumor growth.
"Delivering a large protein complex such as apoptin to the innermost
compartment of tumor cells was a challenge, but the reversible polymer
encapsulation strategy was very effective in protecting and escorting the cargo
in its functional form," said Muxun Zhao, lead author of the research and a
graduate student in chemical and biomolecular engineering at UCLA.
Tang's group continues to research ways of more precisely targeting tumors, prolonging the circulation time of the capsules and delivering other highly sought-after proteins to cancer cells.
The research team also included former UCLA Engineering student Zhen Gu, now an assistant professor in the joint biomedical engineering department at the University of North Carolina at Chapel Hill and North Carolina State University, and University of Southern California researchers including graduate student Biliang Hu, postdoctoral scholar Kye-Il Joo and associate professor Pin Wang.
The Nano Today paper also will be published in a future print edition of the journal.
Source: University of California - Los Angeles
Tang's group continues to research ways of more precisely targeting tumors, prolonging the circulation time of the capsules and delivering other highly sought-after proteins to cancer cells.
The research team also included former UCLA Engineering student Zhen Gu, now an assistant professor in the joint biomedical engineering department at the University of North Carolina at Chapel Hill and North Carolina State University, and University of Southern California researchers including graduate student Biliang Hu, postdoctoral scholar Kye-Il Joo and associate professor Pin Wang.
The Nano Today paper also will be published in a future print edition of the journal.
Source: University of California - Los Angeles
No hay comentarios:
Publicar un comentario